



**RESEARCH
MEDICAL CENTER**

November 2, 2021

**U.S. Nuclear Regulatory Commission
Region III
Materials Licensing Section
2443 Warrensville Road, Suite 210
Lisle, Illinois 60532-4352**

RE: Notification Request, License 24-18625-01

I am submitting a notification as described under 10 CFR 35.14 for radioactive materials license 24-18625-01 issued to Research Medical Center. The requested changes are:

Item 12 (B): Add Jared L. Hodgson, MD as an Authorized User for 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

Attached you will find the following document supporting this request:

- NRC Materials License number 24-24405-01 for Belton Regional Medical Center, listing Jared L. Hodgson, MD as an Authorized User for 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).**

Should you need further information or have any questions, please contact Radiation Safety Officer Josh McIlvain at 913-424-3640.

Thank you,

A handwritten signature in black ink, appearing to read "Johnathon Myers".

**Johnathon Myers
Chief Operating Officer
Research Medical Center**

RECEIVED NOV 05 2021

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Midwest Division - RBH, LLC d/b/a Belton Regional Medical Center 2. 17065 S. 71 Hwy. Belton, MO 64012		In accordance with application dated March 18, 2021,	4. Expiration Date: September 30, 2036
		3. License No.: 24-24405-01 is renewed in its entirety to read as follows:	5. Docket No.: 030-18606 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-24405-01

Docket or Reference No.:

030-18606

Amendment No. 30

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 17065 S. 71 Hwy., Belton, Missouri, 64012.
11. The Radiation Safety Officer (RSO) for this license is Joshua R. McIlvain, MS.
12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)**Material and Use**

Michael E. Farber, M.D.

10 CFR 35.100, 10 CFR 200, 10 CFR 300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Barry A. Gubin, M.D.

10 CFR 35.100, 10 CFR 200, 10 CFR 300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Ryan M. Hegg, M.D.

10 CFR 35.100, 10 CFR 200, 10 CFR 300 (limited to the oral administration of sodium iodide I-131 and parenteral administration of any beta emitter or photon-emitting radionuclide with a photon energy less than 150 keV)

Jared L. Hodgson, M.D.

10 CFR 35.100, 10 CFR 200, 10 CFR 300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Graham K. Lee, M.D.

10 CFR 35.100, 10 CFR 35.200

Kevin L. Litwin, M.D.

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-24405-01

Docket or Reference No.:

030-18606

Amendment No. 30

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 18, 2021 (ML21083A233)

B. Letter dated June 15, 2021 (ML21176A044)

Date: September 20, 2021

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Cassandra F. Frazier

By:

Cassandra F. Frazier
Region 3

Digitally signed by Cassandra F.

Frazier

Date: 2021.09.20 17:55:44 -05'00'